Loes W S Engels
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Loes W S Engels has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Heike Gerger
Department of Family Medicine Care and Public Health Research Institute Maastricht University Maastricht the Netherlands
1 shared publicationHenri Stoffers
Department of Family Medicine Care and Public Health Research Institute Maastricht University Maastricht the Netherlands
1 shared publication- Jany Rademakers
Department of Family Medicine, Care and Public Health Research Institute (CAPHRI), Maastricht University
1 shared publication Jesse Jansen
Department of Family Medicine Care and Public Health Research Institute Maastricht University Maastricht the Netherlands
1 shared publicationJolijn Bohnen
Department of Family Medicine Care and Public Health Research Institute Maastricht University Maastricht the Netherlands
1 shared publicationJuliane Menting
Netherlands Institute for Health Services Research (Nivel) , Utrecht
1 shared publication
Latest Publications
- Open Access
- 20 March 2025
- Published by Wiley in Journal of Evidence-Based Medicine
- Vol. 18 (1) , e70015
Medication Management in Patients With Polypharmacy in Primary Care: A Scoping Review of Clinical Practice Guidelines
Objective: Inappropriate polypharmacy increases the risk of medication‐related issues. Adequate management of polypharmacy is a challenge involving different healthcare professionals, complex decision‐making and ideally including patient involvement. The objective of this scoping review was to provide an overview of national recommendations for medication management of patients with polypharmacy in primary care. Methods: A scoping review of clinical practice guidelines focusing on medication management in adults with polypharmacy, applicable to primary care was performed. Databases (G‐I‐N, Turning Research into Practice and PubMed), network, and a global report were screened for guidelines published after 2000 in English, Dutch, German, Spanish, French, or Russian. Raw data were extracted in duplicate using an extraction framework focusing on strategies, involvement of professionals, patient involvement, and implementation. Qualitative content analysis was used. Guideline quality was assessed using AGREE‐II. The study was registered with the Open Science Framework. Results: Eight guidelines originating from eight countries were included. The most common recommended strategy was a medication review conducted by a general practitioner and/or a community pharmacist. Tasks and target population differed per guideline. Most guidelines recommended involving the patient in the process, mostly to elicit the patient's experiences and treatment goals. Few guidelines included advice on the implementation of recommendations. Three out of eight guidelines were of good quality (AGREE‐II score >70% in 5/6 domains). Conclusions: Most guidelines recommended a medication review, with patient involvement, as a strategy for medication management in polypharmacy in primary care. Guidance on task division and implementation of guidelines in practice was less clear. This review illustrates room for guideline improvements.
- 20 March 2025
- Published by Wiley in Journal of Evidence-Based Medicine
- Vol. 18 (1) , e70015
Open AccessMedication Management in Patients With Polypharmacy in Primary Care: A Scoping Review of Clinical Practice Guidelines
Objective: Inappropriate polypharmacy increases the risk of medication‐related issues. Adequate management of polypharmacy is a challenge involving different healthcare professionals, complex decision‐making and ideally including patient involvement. The objective of this scoping review was to provide an overview of national recommendations for medication management of patients with polypharmacy in primary care. Methods: A scoping review of clinical practice guidelines focusing on medication management in adults with polypharmacy, applicable to primary care was performed. Databases (G‐I‐N, Turning Research into Practice and PubMed), network, and a global report were screened for guidelines published after 2000 in English, Dutch, German, Spanish, French, or Russian. Raw data were extracted in duplicate using an extraction framework focusing on strategies, involvement of professionals, patient involvement, and implementation. Qualitative content analysis was used. Guideline quality was assessed using AGREE‐II. The study was registered with the Open Science Framework. Results: Eight guidelines originating from eight countries were included. The most common recommended strategy was a medication review conducted by a general practitioner and/or a community pharmacist. Tasks and target population differed per guideline. Most guidelines recommended involving the patient in the process, mostly to elicit the patient's experiences and treatment goals. Few guidelines included advice on the implementation of recommendations. Three out of eight guidelines were of good quality (AGREE‐II score >70% in 5/6 domains). Conclusions: Most guidelines recommended a medication review, with patient involvement, as a strategy for medication management in polypharmacy in primary care. Guidance on task division and implementation of guidelines in practice was less clear. This review illustrates room for guideline improvements.
- Open Access
- 25 October 2023
- Published by Oxford University Press (OUP) in Family Practice
- Vol. 41 (6) , 901-908
Measurement of treatment burden in patients with multimorbidity in the Netherlands: translation and validation of the Multimorbidity Treatment Burden Questionnaire (NL-MTBQ)
Multimorbidity is a growing problem. The number and complexity of (non-)pharmaceutical treatments create a great burden for patients. Treatment burden refers to the perception of the weight of these treatments, and is associated with multimorbidity. Measurement of treatment burden is of great value for optimizing treatment and health-related outcomes. We aim to translate and validate the Multimorbidity Treatment Burden Questionnaire (MTBQ) for use in the Dutch population with multimorbidity and explore the level of treatment burden. Translating the MTBQ into Dutch included forward–backward translation, piloting, and cognitive interviewing (n = 8). Psychometric properties of the questionnaire were assessed in a cross-sectional study of patients with multimorbidity recruited from a panel in the Netherlands (n = 959). We examined item properties, dimensionality, internal consistency reliability, and construct validity. The level of treatment burden in the population was assessed. The mean age among 959 participants with multimorbidity was 69.9 (17–96) years. Median global NL-MTBQ score was 3.85 (interquartile range 0–9.62), representing low treatment burden. Significant floor effects were found for all 13 items of the instrument. Factor analysis supported a single-factor structure. The NL-MTBQ had high internal consistency (α = 0.845), and provided good evidence on the construct validity of the scale. The Dutch version of the 13-item MTBQ is a single-structured, valid, and compact patient-reported outcome measure to assess treatment burden in primary care patients with multimorbidity. It could identify patients experiencing high treatment burden, with great potential to enhance shared decision-making and offer additional support.
- 25 October 2023
- Published by Oxford University Press (OUP) in Family Practice
- Vol. 41 (6) , 901-908
Open AccessMeasurement of treatment burden in patients with multimorbidity in the Netherlands: translation and validation of the Multimorbidity Treatment Burden Questionnaire (NL-MTBQ)
Multimorbidity is a growing problem. The number and complexity of (non-)pharmaceutical treatments create a great burden for patients. Treatment burden refers to the perception of the weight of these treatments, and is associated with multimorbidity. Measurement of treatment burden is of great value for optimizing treatment and health-related outcomes. We aim to translate and validate the Multimorbidity Treatment Burden Questionnaire (MTBQ) for use in the Dutch population with multimorbidity and explore the level of treatment burden. Translating the MTBQ into Dutch included forward–backward translation, piloting, and cognitive interviewing (n = 8). Psychometric properties of the questionnaire were assessed in a cross-sectional study of patients with multimorbidity recruited from a panel in the Netherlands (n = 959). We examined item properties, dimensionality, internal consistency reliability, and construct validity. The level of treatment burden in the population was assessed. The mean age among 959 participants with multimorbidity was 69.9 (17–96) years. Median global NL-MTBQ score was 3.85 (interquartile range 0–9.62), representing low treatment burden. Significant floor effects were found for all 13 items of the instrument. Factor analysis supported a single-factor structure. The NL-MTBQ had high internal consistency (α = 0.845), and provided good evidence on the construct validity of the scale. The Dutch version of the 13-item MTBQ is a single-structured, valid, and compact patient-reported outcome measure to assess treatment burden in primary care patients with multimorbidity. It could identify patients experiencing high treatment burden, with great potential to enhance shared decision-making and offer additional support.